SpringWorks Therapeutics
SWTX
SWTX was delisted on the 30th of June, 2025.
92 hedge funds and large institutions have $1.79B invested in SpringWorks Therapeutics in 2020 Q3 according to their latest regulatory filings, with 18 funds opening new positions, 29 increasing their positions, 30 reducing their positions, and 4 closing their positions.
350% more first-time investments, than exits
New positions opened: 18 | Existing positions closed: 4
222% more capital inflows, than outflows
Capital inflows: $165M | Capital outflows: $51.3M
20% more funds holding in top 10
Funds holding in top 10: 5 → 6 (+1)
18% more funds holding
Funds holding: 78 → 92 (+14)
6.2% more ownership
Funds ownership: 80.93% → 87.13% (+6.2%)
3% less repeat investments, than reductions
Existing positions increased: 29 | Existing positions reduced: 30
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
+$35.2M |
| 2 |
CCM
Consonance Capital Management
New York
|
+$25.7M |
| 3 |
PAMU
Pictet Asset Management (UK)
London,
United Kingdom
|
+$24.7M |
| 4 |
Victory Capital Management
San Antonio,
Texas
|
+$21.4M |
| 5 |
State Street
Boston,
Massachusetts
|
+$17.9M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BI
BVF Inc
San Francisco,
California
|
-$9.92M |
| 2 |
Citadel Advisors
Miami,
Florida
|
-$7.07M |
| 3 |
SB
Samsara BioCapital
Palo Alto,
California
|
-$6.79M |
| 4 |
Millennium Management
New York
|
-$5.66M |
| 5 |
LGM
Logos Global Management
San Francisco,
California
|
-$4.62M |
SWTX Hedge Fund Activity: Q3 2020 in Review
92 of the 4,972 institutional investors tracked by Wall St. Rank reported a position in SpringWorks Therapeutics (SWTX) for Q3 2020, worth a combined $1.79B — up 22% from $1.46B a quarter earlier.
Buyers outnumbered sellers: 18 funds opened new SWTX positions and 4 closed out — a net gain of 14 holders — while 29 added to existing stakes and 30 trimmed.
The largest buyer was Fidelity Investments, adding an estimated $35.2M. The largest seller was BVF Inc, cutting an estimated $9.92M.
- 92 institutional investors held SpringWorks Therapeutics (SWTX) as of Q3 2020, up from 78 in Q2 2020.
- Funds reported $1.79B of SpringWorks Therapeutics stock for Q3 2020, up 22% quarter-over-quarter.
- 18 funds opened new SpringWorks Therapeutics positions in Q3 2020 and 4 closed out, a net change of +14 holders.
- The largest SpringWorks Therapeutics buyer in Q3 2020 was Fidelity Investments, an estimated $35.2M added.
- The largest SpringWorks Therapeutics seller in Q3 2020 was BVF Inc, an estimated $9.92M sold.
Based on aggregated 13F filings for Q3 2020.